Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex

Neoplasia (United States)

Volumn 15, Issue 5, 2013, Pages 511-522

  Piazza, Rocco ^a   Magistroni, Vera ^a   Mogavero, Angela ^a   Andreoni, Federica ^a   Ambrogio, Chiara ^b   Chiarle, Roberto ^b   Mologni, Luca ^a   Bachmann, Petra S ^c,d   Lock, Richard B ^c,d   Collini, Paola ^e   Pelosi, Giuseppe ^e,f   Gambacorti Passerini, Carlo ^a,g  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE INHIBITOR; AZACITIDINE; BETA GLUCURONIDASE; BIM PROTEIN; BISULFITE; DNA METHYLTRANSFERASE INHIBITOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE DEACETYLASE 1; METHYL CPG BINDING PROTEIN 2; PHOSPHOTRANSFERASE INHIBITOR; THYMIDINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; 5' UNTRANSLATED REGION; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; CHROMATIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MECP2 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; P80(NPM-ALK) PROTEIN; PROTEIN TYROSINE KINASE; REPRESSOR PROTEIN; SIN3A TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CHROMATIN CONDENSATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DENSITOMETRY; DNA METHYLATION; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOID CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION INITIATION SITE; UPREGULATION; WESTERN BLOTTING; 5' UNTRANSLATED REGION; ACETYLATION; CASE CONTROL STUDY; CELL SURVIVAL; CHROMATIN; CPG ISLAND; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PROTEIN PROCESSING; TUMOR CELL LINE;

5' UNTRANSLATED REGIONS; ACETYLATION; APOPTOSIS REGULATORY PROTEINS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MEMBRANE PROTEINS; METHYL-CPG-BINDING PROTEIN 2; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS;

EID: 84877057244     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121784     Document Type: Article

References (53)

1. Fletcher JI and Huang DC (2008). Controlling the cell death mediators Bax and Bak: puzzles and conundrums. Cell Cycle 7, 39-44. E-pub 2007 Oct 2016.
2. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM, and Strasser A (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735-1738.
3. Egle A, Harris AW, Bouillet P, and Cory S (2004). Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101, 6164-6169. E-pub 2004 Apr 6112.
4. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, Morishima Y, Nakamura S, and Seto M (2005). Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24, 1348-1358.
5. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, and Ehrlich M (1983). The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 11, 6883-6894.
6. Baylin SB and Herman JG (2000). DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16, 168-174.
7. Toyota M and Issa JP (2005). Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32, 521-530.
8. Strathdee G, Davies BR, Vass JK, Siddiqui N, and Brown R (2004). Cell typespecific methylation of an intronic CpG island controls expression of the MCJ gene. Carcinogenesis 25, 693-701.
9. Parolini O, Weinhausel A, Kagerbauer B, Sassmann J, Holter W, Gadner H, Haas OA, and Knapp W (2003). Differential methylation pattern of the X-linked lymphoproliferative (XLP) disease gene SH2D1A correlates with the cell lineagespecific transcription. Immunogenetics 55, 116-121.
10. Petak I, Danam RP, Tillman DM, Vernes R, Howell SR, Berczi L, Kopper L, Brent TP, and Houghton JA (2003). Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 10, 211-217.
11. Esteller M (2003). Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 109, 80-88.
12. San Jose-Eneriz E, Agirre X, Jimenez-Velasco A, Cordeu L, Martin V, Arqueros V, Garate L, Fresquet V, Cervantes F, Martinez-Climent JA, et al. (2009). Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer 45, 1877-1889.
13. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, and Allday MJ (2009). Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5, e1000492.
14. Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, Kirschnek S, Hartmann C, Fritsch RM, Gillissen B, Daniel PT, et al. (2007). Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 26, 7038-7048.
15. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, Fresquet V, Beltran E, Agirre X, Marugan I, Marin M, et al. (2007). Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109, 271-280. E-pub 2006 Sep 2007.
16. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, et al. (2010). Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 116, 3013-3022. E-pub 2010 Jul 3020.
17. Leo E, Mancini M, Aluigi M, Castagnetti F, Martinelli G, Barbieri E, and Santucci MA (2012). DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia. Br J Haematol 159, 373-376.
18. Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, Calasanz MJ, Panizo C, Richter JA, Hernandez JM, et al. (2010). Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 116, 2531-2542.
19. Gu TL, Tothova Z, Scheijen B, Griffin JD, Gilliland DG, and Sternberg DW (2004). NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood 103, 4622-4629. E-pub 2004 Feb 4612.
20. Dijkers PF, Medema RH, Lammers JW, Koenderman L, and Coffer PJ (2000). Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10, 1201-1204.
21. Ambrogio C, Martinengo C, Voena C, Tondat F, Riera L, di Celle PF, Inghirami G, and Chiarle R (2009). NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res 69, 8611-8619. E-pub 2009 Nov 8613.
22. Galietta A, Gunby RH, Redaelli S, Stano P, Carniti C, Bachi A, Tucker PW, Tartari CJ, Huang CJ, Colombo E, et al. (2007). NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood 110, 2600-2609. E-pub 2007 May 2630.
23. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, et al. (2007). Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27, 4784-4795. E-pub 2007 Apr 4730.
24. Laird PW (2005). Cancer epigenetics. Hum Mol Genet 14, R65-R76.
25. Brown R and Strathdee G (2002). Epigenomics and epigenetic therapy of cancer. Trends Mol Med 8, S43-S48.
26. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, and Eisenman RN (1997). Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89, 349-356.
27. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, and Reinberg D (1999). Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 13, 1924-1935.
28. Li J, Wang J, Nawaz Z, Liu JM, Qin J, and Wong J (2000). Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J 19, 4342-4350.
29. Perissi V, Jepsen K, Glass CK, and Rosenfeld MG (2010). Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet 11, 109-123.
30. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, and Wolffe AP (1998). Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19, 187-191.
31. Kokura K, Kaul SC, Wadhwa R, Nomura T, Khan MM, Shinagawa T, Yasukawa T, Colmenares C, and Ishii S (2001). The Ski protein family is required for MeCP2-mediated transcriptional repression. J Biol Chem 276, 34115-34121. E-pub 32001 Jul 34115.
32. Yoon HG, Chan DW, Reynolds AB, Qin J, and Wong J (2003). N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. Mol Cell 12, 723-734.
33. Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, and Esteller M (2003). The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res 31, 1765-1774.
34. Jeltsch A (2006). On the enzymatic properties of Dnmt1: specificity, processivity, mechanism of linear diffusion and allosteric regulation of the enzyme. Epigenetics 1, 63-66. E-pub 2006 Apr 2005.
35. Takezawa K, Okamoto I, Nishio K, Janne PA, and Nakagawa K (2011). Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitorinduced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 17, 2140-2148.
36. Allen LF, Sebolt-Leopold J, and Meyer MB (2003). CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30, 105-116.
37. Bouillet P, Cory S, Zhang LC, Strasser A, and Adams JM (2001). Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. Dev Cell 1, 645-653.
38. Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, Kappler J, and Marrack P (2002). Activated T cell death in vivo mediated by proapoptotic Bcl-2 family member Bim. Immunity 16, 759-767.
39. Ley R, Balmanno K, Hadfield K, Weston C, and Cook SJ (2003). Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278, 18811-18816.
40. Akiyama T, Bouillet P, Miyazaki T, Kadono Y, Chikuda H, Chung UI, Fukuda A, Hikita A, Seto H, Okada T, et al. (2003). Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J 22, 6653-6664.
41. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, and Auberger P (2003). Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22, 6785-6793.
42. Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B, Alix S, Youle RJ, LaMarche A, Maroney AC, et al. (2003). JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 38, 899-914.
43. Biswas SC and Greene LA (2002). Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation. J Biol Chem 277, 49511-49516.
44. Shinjyo T, Kuribara R, Inukai T, Hosoi H, Kinoshita T, Miyajima A, Houghton PJ, Look AT, Ozawa K, and Inaba T (2001). Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol 21, 854-864.
45. Jones PA and Baylin SB (2007). The epigenomics of cancer. Cell 128, 683-692.
46. Ting AH, McGarvey KM, and Baylin SB (2006). The cancer epigenome- components and functional correlates. Genes Dev 20, 3215-3231.
47. Tate PH and Bird AP (1993). Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 3, 226-231.
48. Watt F and Molloy PL (1988). Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev 2, 1136-1143.
49. Klose RJ and Bird AP (2006). Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31, 89-97. E-pub 2006 Jan 2005.
50. Shahbazian MD and Grunstein M (2007). Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76, 75-100.
51. Le Guezennec X, Vermeulen M, Brinkman AB, Hoeijmakers WA, Cohen A, Lasonder E, and Stunnenberg HG (2006). MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol 26, 843-851.
52. Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS, Medema RH, and Lam EW(2005). Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 24, 2317-2329.
53. Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM, and Medema RH (2002). The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 168, 5024-5031.